Donald Trump has rescinded an executive order from President Joe Biden that sought to lower the price of drugs.
The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so ...
Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs ...
Iowa, Jan. 23 introduced the Drug-price Transparency for Consumers Act, legislation supported by the AHA that would require price disclosures on advertisements for prescription drugs. The bill would ...
The FDA has accepted for review the New Drug Application for plozasiran for the treatment for familial chylomicronemia syndrome.
Since the announcement that president-elect Donald Trump would nominate Robert F. Kennedy Jr. (RFK Jr.) as the secretary of the U.S. Department ...
The Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for elamipretide for the treatment of Barth syndrome, a rare genetic disorder.
On Day 1 of his second term of office, Trump rescinded Biden's Executive Order 14087, "Lowering Prescription Drug Costs for ...
The FDA has accepted the BLA for lecanemab-irmb SC for weekly maintenance dosing in the treatment of early Alzheimer disease.
On January 15, 2025, the US Drug Enforcement Administration (DEA) released a proposed rule entitled Special Registrations for ...
The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) for the treatment of adults with locally advanced ...
Both individual Medicare Part D plans and Medicare Advantage Part D (MAPD) plans have drug lists specific to their plans. Medicare prescription plans use their formularies to reduce drug costs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback